370 related articles for article (PubMed ID: 30248938)
1. Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.
Toljan K; Vrooman B
Med Sci (Basel); 2018 Sep; 6(4):. PubMed ID: 30248938
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain Syndromes.
Trofimovitch D; Baumrucker SJ
Am J Hosp Palliat Care; 2019 Oct; 36(10):907-912. PubMed ID: 30917675
[TBL] [Abstract][Full Text] [Related]
3. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
Younger J; Parkitny L; McLain D
Clin Rheumatol; 2014 Apr; 33(4):451-9. PubMed ID: 24526250
[TBL] [Abstract][Full Text] [Related]
4. The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders.
Patten DK; Schultz BG; Berlau DJ
Pharmacotherapy; 2018 Mar; 38(3):382-389. PubMed ID: 29377216
[TBL] [Abstract][Full Text] [Related]
5. Low dose naltrexone for induction of remission in Crohn's disease.
Segal D; Macdonald JK; Chande N
Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033
[TBL] [Abstract][Full Text] [Related]
6. Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice.
Crain SM; Shen KF
Brain Res; 2007 Sep; 1167():31-41. PubMed ID: 17692296
[TBL] [Abstract][Full Text] [Related]
7. Low-dose naltrexone and opioid consumption: a drug utilization cohort study based on data from the Norwegian prescription database.
Raknes G; Småbrekke L
Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):685-693. PubMed ID: 28370746
[TBL] [Abstract][Full Text] [Related]
8. Low Dose Naltrexone in Dermatology.
Jaros J; Lio P
J Drugs Dermatol; 2019 Mar; 18(3):235-238. PubMed ID: 30909326
[TBL] [Abstract][Full Text] [Related]
9. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
Ludwig MD; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
[TBL] [Abstract][Full Text] [Related]
10. Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review.
Kim PS; Fishman MA
Curr Pain Headache Rep; 2020 Aug; 24(10):64. PubMed ID: 32845365
[TBL] [Abstract][Full Text] [Related]
11. Use of low-dose naltrexone in the treatment of severe Hailey-Hailey disease: One case report.
Garayar Cantero M; Canseco Martín M; Aguado García Á; Ruiz-Sánchez D; Valtueña J; Manchado López P
Dermatol Ther; 2019 May; 32(3):e12892. PubMed ID: 30958613
[TBL] [Abstract][Full Text] [Related]
12. Intermittent blockade of OGFr and treatment of autoimmune disorders.
Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2018 Dec; 243(17-18):1323-1330. PubMed ID: 30541348
[TBL] [Abstract][Full Text] [Related]
13. Duration of opioid receptor blockade determines biotherapeutic response.
McLaughlin PJ; Zagon IS
Biochem Pharmacol; 2015 Oct; 97(3):236-46. PubMed ID: 26119823
[TBL] [Abstract][Full Text] [Related]
14. Low doses of cyclic AMP-phosphodiesterase inhibitors rapidly evoke opioid receptor-mediated thermal hyperalgesia in naïve mice which is converted to prominent analgesia by cotreatment with ultra-low-dose naltrexone.
Crain SM; Shen KF
Brain Res; 2008 Sep; 1231():16-24. PubMed ID: 18656459
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone.
Oaks Z; Stage A; Middleton B; Faraone S; Johnson B
Discov Med; 2018 Nov; 26(144):197-206. PubMed ID: 30695679
[TBL] [Abstract][Full Text] [Related]
16. PTI-609: a novel analgesic that binds filamin A to control opioid signaling.
Burns LH; Wang HY
Recent Pat CNS Drug Discov; 2010 Nov; 5(3):210-20. PubMed ID: 20726836
[TBL] [Abstract][Full Text] [Related]
17. Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: A Case Series.
McKenzie-Brown AM; Boorman DW; Ibanez KR; Agwu E; Singh V
J Pain Res; 2023; 16():1993-1998. PubMed ID: 37337611
[TBL] [Abstract][Full Text] [Related]
18. Naltrexone at low doses (LDN) and its relevance to cancer therapy.
Liu WM; Dalgleish AG
Expert Rev Anticancer Ther; 2022 Mar; 22(3):269-274. PubMed ID: 35107043
[TBL] [Abstract][Full Text] [Related]
19. Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases.
Dara P; Farooqui Z; Mwale F; Choe C; van Wijnen AJ; Im HJ
Biomedicines; 2023 Jun; 11(6):. PubMed ID: 37371715
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
